Are Series A radically growing?

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...